US4622221004
US4622221004
Ionis Pharmaceuticals, Inc.
Loading chart...
Elevated Business & Solvency Risk
Caution: In addition to price volatility, there are balance sheet risks due to higher debt or weaker liquidity (Health Score: 25/100).
Volatility Risk
Transparent evaluation of price volatility (SRI), Beta, and historical drawdowns.
Volatility Risk Score
7/7 Very High
7 / 7 SRI Price Fluctuation & Beta
Very high volatility or fundamental risks. Significant loss potential; strictly for aggressive investors. Moves noticeably less than the broader market (0.4x).
Beta (Market Relation)
0.38x
DefensiveVolatility (5Y p.a.)
44.2% p.a.
5-Year HorizonMax Drawdown (5Y)
-52.4%
5-Year HorizonSharpe Ratio
0.05
Return / RiskSpeculative / High Risk: Score Basis:
Multi-Horizon Risk & Performance Matrix
Historical volatility, drawdowns, and risk-adjusted return across 1, 3, 5, and 10 years.
High Volatility
Timeframe | Volatility (p.a.) | Max Drawdown | Sharpe Ratio | Return (p.a.) |
|---|---|---|---|---|
| 1 Year | — | — | — | -38.1% |
| 3 Years | 44.6% | -52.4% | -0.11 | -2.3% |
| 5 Years | 44.2% | -52.4% | 0.05 | +4.9% |
| 10 Years | 45.6% | -70.4% | -0 | +2.4% |
Automated Risk & Health Notes (Red Flags)
Single Stock Risk: Investing in an individual stock carries full company and insolvency risk (no fund diversification).
Critical leverage: Debt-to-Equity is at 498%.
Unprofitable business model: The company is currently generating net losses.
Structurally High Volatility: Above-average fluctuations persist across 5 to 10 years (44.2% p.a.).
Historical Stress Test: Maximum peak-to-trough drawdown of -70.4% in the extended horizon.
Corporate Governance & ISS Scores
Overall Governance Risk
3 ISS Score: 3 / 10
Audit Risk
6 ISS Score: 6 / 10
Board Risk
3 ISS Score: 3 / 10
Short Ratio
6.60